Henry Schein is reorganizing its leadership structure to simplify its business and improve execution on its goals. The dental and medical products provider is creating a new leadership team to replace its executive management committee.
The company will also integrate its global supply chain and distribution organizations to help speed decision-making. This move comes months after Fred Lowery was named CEO and the company deepened its relationship with private equity firm KKR.
As part of the changes, Chief Operating Officer Michael Ettinger, Chief Strategy Officer Mark Mlotek, and James Mullins, senior vice president of global supply chain, will step down from their posts effective Oct. 30. The three longtime executives will remain senior advisers to the company.
The reorganization, under new CEO Fred Lowery, comes after Henry Schein’s board late last year gave KKR the right to increase its stake in the company to up to 19.9%. KKR gained an approximately 12% stake in Henry Schein in May 2025.
Evercore ISI analyst Elizabeth Anderson said the new executive-level reorganization represents the most significant change at the company since Lowery took over as CEO earlier this year. The creation of a new leadership team signals that Lowery is willing to make large changes to help the company thrive.
Anderson wrote in a note to clients, “We see Fred’s creation of a new leadership team as a signal that he is not bound by traditional ways of doing business at Henry Schein and will make large changes if necessary to help the company thrive on a go-forward basis.”
Related: User Account Blocked by Social Media Platform
In practice, this development may mean that Henry Schein will be able to respond more quickly to changes in the market, which could benefit the company’s customers, such as dental and medical offices. They will be able to simplify their business and improve execution on their goals, which may also lead to increased efficiency and cost savings.
Henry Schein is a leading supplier of healthcare products to dental and medical offices, with over $13 billion in annual sales. When the company agreed to allow KKR to expand its ownership stake, it expected to improve its operating income by over $200 million over the next few years.
Lowery joined Henry Schein as CEO in March from Thermo Fisher Scientific, where he was president of laboratory products and bioproduction. He succeeded Stanley Bergman, whose tenure as Henry Schein CEO spanned 35 years.
In May, Bergman also retired as chairman, and the board elected William “Dan” Daniel, an executive adviser to KKR, to fill that role. Daniel, a former Danaher executive, joined the Henry Schein board in May 2025 in connection with KKR’s $250 million investment in the company, which is a significant partnership in the healthcare industry.
Henry Schein is scheduled to report second-quarter earnings on Tuesday.
